Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.

Journal Article (Journal Article)

The in vitro activities of fungal CYP51 inhibitors VT-1161 and VT-1129 were determined for Candida glabrata (n = 34) and C. krusei (n = 50). C. glabrata isolates were screened for FKS gene mutations. All isolates were resistant clinically and/or in vitro to at least one standard antifungal compound. VT-1161 and VT-1129 MICs for all isolates were at least 5-fold below achievable human plasma levels for VT-1161. VT-1161 and VT-1129 are promising for the treatment of resistant C. glabrata and C. krusei infections.

Full Text

Duke Authors

Cited Authors

  • Schell, WA; Jones, AM; Garvey, EP; Hoekstra, WJ; Schotzinger, RJ; Alexander, BD

Published Date

  • March 2017

Published In

Volume / Issue

  • 61 / 3

PubMed ID

  • 27956419

Pubmed Central ID

  • PMC5328539

Electronic International Standard Serial Number (EISSN)

  • 1098-6596

Digital Object Identifier (DOI)

  • 10.1128/AAC.01817-16


  • eng

Conference Location

  • United States